Publications by authors named "Janine Spreuer"
Article Synopsis
- - This study introduces a new high-dimensional technique to analyze human γδ T cell subsets in their natural tissue settings, overcoming previous challenges related to antibody availability and technology limitations.
- - Researchers utilized a combination of multiplexed imaging and bioinformatics to identify and characterize γδ T cells in colon and colorectal cancer samples, uncovering various microenvironments and their interactions with both immune and cancer cells.
- - Although this initial study shows the promise of this advanced technology for exploring T cell diversity and microenvironments, further research is needed to connect specific T cell characteristics and microenvironment features with important clinical factors.
Background: The need for reliable clinical biomarkers to predict which patients with melanoma will benefit from immune checkpoint blockade (ICB) remains unmet. Several different parameters have been considered in the past, including routine differential blood counts, T cell subset distribution patterns and quantification of peripheral myeloid-derived suppressor cells (MDSC), but none has yet achieved sufficient accuracy for clinical utility.
Methods: Here, we investigated potential cellular biomarkers from clinical routine blood counts as well as several myeloid and T cell subsets, using flow cytometry, in two independent cohorts of a total of 141 patients with stage IV M1c melanoma before and during ICB.
Immune checkpoint blockade (ICB) is standard-of-care for patients with metastatic melanoma. It may re-invigorate T cells recognizing tumors, and several tumor antigens have been identified as potential targets. However, little is known about the dynamics of tumor antigen-specific T cells in the circulation, which might provide valuable information on ICB responses in a minimally invasive manner.
View Article and Find Full Text PDFArticle Synopsis
- Anti-PD-1 antibodies are used for treating metastatic melanoma, but only some patients respond; understanding T cell activity and biomarkers could improve outcomes.
- Researchers studied T cells reactive to NY-ESO-1 and Melan-A in 111 stage IV melanoma patients during treatment to see if they could predict survival.
- Results indicated that T cells that were initially present but disappeared during treatment were associated with longer progression-free and overall survival, suggesting beneficial changes in T cell distribution in response to therapy.
Immune checkpoint blockade with anti-PD-1 antibodies is showing great promise for patients with metastatic melanoma and other malignancies, but despite good responses by some patients who achieve partial or complete regression, many others still do not respond. Here, we sought peripheral blood T-cell biomarker candidates predicting treatment outcome in 75 stage IV melanoma patients treated with anti-PD-1 antibodies. We investigated associations with clinical response, progression-free survival (PFS) and overall survival (OS).
View Article and Find Full Text PDF